Last reviewed: June 23, 2026
Last updated: June 23, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy received FDA approval on November 16, 2021, becoming the first GLP-1 receptor agonist approved specifically for chronic weight management in adults with obesity or overweight conditions. This decision opened the door to a new category of prescription weight loss medications that work by regulating appetite hormones in the brain.
The FDA Approval Timeline for Semaglutide Weight Loss
The journey to Wegovy's approval began years before 2021. Novo Nordisk, the pharmaceutical company behind semaglutide, initially developed the medication for type 2 diabetes management under the brand name Ozempic. During clinical trials for diabetes, researchers noticed participants were experiencing significant weight loss as a side effect. This observation led to dedicated trials testing semaglutide's effectiveness specifically for weight management in people without diabetes.
In June 2021, the FDA's advisory committee voted unanimously to recommend approval of Wegovy for chronic weight management. The recommendation came after reviewing data from the STEP trial program, which followed thousands of participants over 68 weeks. Participants taking semaglutide lost an average of 15% of their body weight, compared to 2.4% in the placebo group. The FDA formally approved Wegovy on November 16, 2021, and the medication became available to patients in the United States the following year.
How Semaglutide Works for Weight Loss Management
Semaglutide functions by mimicking glucagon-like peptide-1 (GLP-1), a hormone that controls hunger and blood sugar levels. When semaglutide activates GLP-1 receptors in the brain, it slows stomach emptying, increases feelings of fullness, and reduces overall appetite. This mechanism means patients naturally consume fewer calories without relying on willpower alone. The medication addresses the biological systems that drive weight gain, rather than simply restricting food intake through behavior change.
Clinical evidence shows semaglutide's effectiveness extends beyond appetite suppression. The medication also improves insulin sensitivity, reduces fat storage in the liver, and may support cardiovascular health. Studies published after the initial approval demonstrated that people maintaining semaglutide treatment sustained their weight loss over multiple years, while those who stopped the medication gradually regained weight. This pattern reflects semaglutide's role in resetting hunger regulation rather than producing permanent metabolic changes.
PlexusDx Compounded Semaglutide vs. Brand Name Wegovy
PlexusDx offers compounded semaglutide injections from licensed 503A compounding pharmacies at significantly lower costs than brand-name Wegovy. While Wegovy typically costs $900–$1,400 per month through retail pharmacies, PlexusDx compounded semaglutide starts at $149 per month without insurance requirements. Both formulations contain the same active ingredient and work identically in the body. The cost difference reflects PlexusDx's direct-to-patient model and access to compounded medications produced under strict pharmaceutical standards.
Compounded medications from 503A pharmacies meet federal standards for sterility, potency, and purity equivalent to brand-name drugs. PlexusDx verifies all compounding partners maintain proper licensure and quality control. Patients can use HSA or FSA accounts to pay for PlexusDx semaglutide, further reducing out-of-pocket expenses. Your dose may need to go up as you progress through treatment. Your price won't—all dosage levels remain at the same flat monthly rate.
Personalized Treatment With PlexusDx Precision Peptide Genetic Testing
Beyond standard semaglutide therapy, PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month) to identify individual predispositions affecting weight loss response. The test analyzes 14 pathways and 49 peptides using key genetic variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. These variants influence how your body responds to GLP-1 medications, appetite regulation capacity, and fat accumulation patterns. Understanding your genetic profile helps PlexusDx specialists recommend whether semaglutide alone or combination therapies may optimize your results.
Genetic insights from the Precision Peptide test guide dose selection, medication choice, and lifestyle recommendations tailored to your biology. Some patients show stronger GLP-1 receptor sensitivity and respond well to lower doses, while others benefit from higher doses or dual-compound protocols. This personalization reduces trial-and-error approaches and increases the likelihood of sustained weight loss success. PlexusDx serves all 50 states with no membership fees, making genetic-guided weight loss accessible regardless of location or insurance status.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
When exactly was Wegovy approved by the FDA for weight loss?
The FDA approved Wegovy (semaglutide) on November 16, 2021, following unanimous recommendation from its advisory committee in June 2021. Approval was based on the STEP trial program, which demonstrated participants lost an average of 15% of body weight over 68 weeks.
Is compounded semaglutide from PlexusDx the same as Wegovy?
Yes, compounded semaglutide contains the identical active ingredient as Wegovy and produces the same biological effects. PlexusDx sources from licensed 503A compounding pharmacies meeting federal quality standards, at a cost starting at $149/month compared to Wegovy's typical $900–$1,400 monthly price.
How much weight can I expect to lose with semaglutide?
Clinical trial data shows average weight loss of 15% of starting body weight with semaglutide treatment. Individual results vary based on adherence, diet, exercise, and genetic factors. PlexusDx's Precision Peptide Genetic Test identifies your personal predispositions to help predict your likely response.
Do I need insurance to access PlexusDx semaglutide?
No—PlexusDx requires no insurance and no membership fees. Treatment starts at $149/month and is HSA/FSA eligible. PlexusDx serves all 50 states with direct-to-patient access, eliminating traditional pharmacy markup and insurance barriers.
What does the PlexusDx Precision Peptide Genetic Test measure?
The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights using variants like GLP1R rs6923761 and FTO rs9939609. It identifies your genetic predispositions to GLP-1 response, appetite regulation, and fat metabolism—guiding personalized treatment selection for optimal weight loss outcomes.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
When Do You See the Most Weight Loss on Wegovy?
Wegovy and Ozempic: Understanding Whether You Can Take Them Together